Community Practice

Latest News


CME Content


A report from the HHS Office of the Inspector General (OIG) has found that most states have not decided whether to use average manufacturer price (AMP) data for Medicaid drug reimbursement due to concerns over the availability and quality of AMP data.

This column challenges you to determine the name of a drug, based on the clues given. See if you can figure it out.

The differences between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are discussed along with emerging treatments for both conditions. The recent withdrawal of tegaserod (Zelnorm) for the treatment of IBS-c has left many searching for new therapies.

The FDA has approved Altabax (retapamulin, GSK) antibacterial ointment, the first in a new class of antibacterials known as the pleuromutilins to treat impetigo.

Health-system pharmacists could raise quality and safety in hospitals. Yet they are underutilized in areas of discharge counseling and drug-abbreviation confusion. Medication errors result.

Three trials at this year's ACC meeting in New Orleans focused on pharmacotherapy effects on cardiovascular disease, one with a strong showing for medical therapy alone versus mechanical intervention.

A new study, published in the Archives of Pediatrics and Adolescent Medicine, concludes that the more cigarette marketing teens are exposed to in retail stores, the more likely they are to smoke, and that restricting these retail marketing practices would reduce smoking among teens.

The FDA is advising consumers not to purchase or use True Man and Energy Max products promoted and sold as dietary supplements throughout the U.S. Both products—touted as sexual enhancement aids and treatments for erectile dysfunction (ED)—are illegal products that contain potentially harmful, undeclared ingredients.

XLHealth Corp. is adding medication therapy management to its Care Improvement Plus Medicare Advantage plan in Arkansas, Georgia, Maryland, Missouri, South Carolina, and Texas.

The use of intravenous (IV) syringes for non-IV applications such as enteral feedings poses many risks, especially for the pediatric and neonatal population which has a majority of their oral and enteral doses provided through a gastric tube. The Baxa Corporation recently announced the launch of a new educational campaign to make healthcare providers aware of these problems and offer solutions.